Abstract 751P
Background
With the introduction of molecular classification of endometrial cancer (EC), the importance of Lynch syndrome and hereditary EC has been emphasized. For a successful conduct of EC-therapy, the patient’s expectations, preferences, and needs should be considered. The aim of this survey was to evaluate the status quo and the patients' understanding of their own condition, including genetic counseling.
Methods
We developed an international online and paper survey with 80 questions for endometrial cancer patients. It included questions on demographics, medical history, tumor classification, therapy, preferences and expectations concerning treatment modalities.
Results
To date, 656 endometrial cancer patients (mean age: 65.0 [20.0; 92.0] years) completed the survey from a total of seven countries, mainly from Germany (56.1%) and Switzerland (40.5%). The majority of patients (77.4 %) were in follow-up and not receiving current cancer therapy, while 16.1 % were still receiving treatment, of which 6.4 % were due to cancer recurrence. Overall, 14.3% of the patients suffered from a recurrent disease. One third of patients (35.1%) reported that their tumor had been tested for molecular classification, and more than half (56.9%) did not know if this had occurred. Genetic counseling was only given to 21.7% of patients, 63.1% did not receive any form of it. From the patients understanding, 19.6% believe that a family history or genetic alteration could be responsible for tumorigenesis – 30.6% do not know. On the contrary, 68.1% of the patients answered that there were cases of cancer in their blood relatives – 19.1% had one or more cases of colorectal cancer in the family history, 13.9% endometrial, 10.9% gastric and 3.9% ovarian cancer. 16.4% of all patients had a second malignancy in their medical history. In general, 32.4 % of patients would like doctors to spend more time on explanations.
Conclusions
This survey underlines the great need for better access to molecular profiling and genetic counseling in women with endometrial cancer. Programs should be developed to empower patients and to educate medical staff.
Clinical trial identification
DRKS-ID: DRKS00025954.
Editorial acknowledgement
Legal entity responsible for the study
NOGGO e.V.
Funding
GSK Research & Development Limited.
Disclosure
J. Sehouli: Financial Interests, Institutional, Research Funding: AstraZeneca, Clovis Oncology, Merck, Pfizer, Tesaro, MSD Oncology, Roche, Bayer, PharmaMar; Financial Interests, Advisory Board: AstraZeneca, Clovis Oncology, PharmaMar, Merck, Pfizer, Tesaro, MSD Oncology, Lilly, Novocure, J&J, Roche, Ingress Health, Riemser, Sobi, GSK, Novartis; Financial Interests, Other, Honoraria, Travel, Accommodation, Expenses: AstraZeneca, Clovis Oncology, Olympus Medical Systems, PharmaMar, Tesaro, MSD Oncology; Financial Interests, Other, Honoraria: Eisai, J&J, Pfizer, Teva, GSK, Bayer; Financial Interests, Advisory Board, Travel, Accommodation, Expenses: Roche Pharma AG. M.L. Heubner: Financial Interests, Advisory Board: GSK, AstraZeneca, Roche; Financial Interests, Speaker, Consultant, Advisor: MSD, Intuitive, Olympus, GSK, AstraZeneca, Roche; Financial Interests, Leadership Role: SERGS (Society of European Gynaecological Surgery SERGS). All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11